Description: 1988 Valuation Actuary Symposium. The speakers in this session addressed the relative volatility of participating whole life versus universal life and the annual-premium versus single- premium basis.

Description: in the insurance industry, machine learning models are increasingly used to make decisions that affect people's lives. In order to ensure that models are fair, they should be audited for bias. There are no hard and fast rules for bias audit; metrics that can be used to evaluate fairness vary depending on the context in which the model is deployed. The presenters in this session present a flexible framework that highlights key considerations in bias evaluation that can be adjusted to suit your process.

Description: The Actuary Vol. 22 , No. 7. This articles explores the dangers posed by many guaranteed-return life insurance and annuity products.

Description: This article reviews the topics discussed at the December 2004 meeting of the Life and Health Actuarial task force. The covered topics include Actuarial Guideline 38 and Reserves for Variable Annuities C-3 Phase 2 reserves.

Description: 1988 Valuation Actuary Symposium. In this session the speaker described the attributes of a UL policy, how his company invested the cash that was built up, valuation of the product, modeling in general, the specific model structure for Universal Life, problems encountered in the modeling process, and some of the more interesting aspects of the results.

Description: This article discusses the the 1998 alternartive XXX model regulations and the potential tax impact on the definition of life insurance and on reserve deductions associated therewith.

Description: This 1979 session is about current developments in Life products. Products discussed: 1. Adjustable life 2. Universal life 3. Indexed coverages 4. Term Insurance plus accumulation fund 5. Level Premium Term to 100 6. Revertible Term

Description: 1999 SOA Regional Meeting, Atlanta. In this session on next-generation UL, the panelists explored 1999 product development issues relating to the general account/non-equity-indexed universal life product.